New cream offers hope for teens with stubborn hand eczema
NCT ID NCT05355818
First seen May 04, 2026 · Last updated May 06, 2026 · Updated 1 time
Summary
This study tested a cream called delgocitinib in 98 teenagers aged 12-17 with moderate to severe chronic hand eczema. Participants applied the cream twice daily for 16 weeks. The goal was to see if the cream could clear or nearly clear the eczema better than a cream with no active ingredient. The study also tracked side effects and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HAND ECZEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
LEO Pharma investigational site
Darlinghurst, 2010, Australia
-
LEO Pharma investigational site
Mitcham, 3132, Australia
-
LEO Pharma investigational site
Phillip, 2606, Australia
-
LEO Pharma investigational site
Woolloongabba, 4102, Australia
-
LEO Pharma investigational site
Brussels, 1200, Belgium
-
LEO Pharma investigational site
Ghent, 9000, Belgium
-
LEO Pharma investigational site
Gilly, 6060, Belgium
-
LEO Pharma investigational site
Liège, 4000, Belgium
-
LEO Pharma investigational site
Edmonton, T6G 1C3, Canada
-
LEO Pharma investigational site
Fredericton, E3B 1G9, Canada
-
LEO Pharma investigational site
Kingston, K7L 2V7, Canada
-
LEO Pharma investigational site
Montreal, H3T 1C5, Canada
-
LEO Pharma investigational site
Red Deer, T4P1K4, Canada
-
LEO Pharma investigational site
St. John's, NL A1E 1V4, Canada
-
LEO Pharma investigational site
Toronto, M2N 3A6, Canada
-
LEO Pharma investigational site
Winnipeg, R3C 0N2, Canada
-
LEO Pharma investigational site
Martigues, Bouches-du-Rhône, 13500, France
-
LEO Pharma investigational site
Nice, 06000, France
-
LEO Pharma investigational site
Reims, 51100, France
-
LEO Pharma investigational site
Toulouse, 31059, France
-
LEO Pharma investigational site
Chorzów, 41-516, Poland
-
LEO Pharma investigational site
Krakow, 30-002, Poland
-
LEO Pharma investigational site
Krakow, 30-033, Poland
-
LEO Pharma investigational site
Krakow, 31-011, Poland
-
LEO Pharma investigational site
Warsaw, 02-625, Poland
-
LEO Pharma investigational site
Wroclaw, 51-503, Poland
-
LEO Pharma investigational site
Alicante, 03010, Spain
-
LEO Pharma investigational site
Barcelona, 08041, Spain
-
LEO Pharma investigational site
Cadiz, 11009, Spain
-
LEO Pharma investigational site
Esplugues de Llobregat, 08950, Spain
-
LEO Pharma investigational site
Fuenlabrada, 28942, Spain
-
LEO Pharma investigational site
Granada, 18016, Spain
-
LEO Pharma investigational site
Ipswich, IP4 5PD, United Kingdom
-
LEO Pharma investigational site
Kings Lynn, PE30 4ET, United Kingdom
-
LEO Pharma investigational site
Lincoln, LN2 5QY, United Kingdom
-
LEO Pharma investigational site
London, SW10 9NH, United Kingdom
-
LEO Pharma investigational site
Walsall, WS2 9PS, United Kingdom
Conditions
Explore the condition pages connected to this study.